tbuckley/cabot-search huggingface dataset:
EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the Epstein–Barr virus
Authors: Lijun Jiang, Rongfeng Lan, Tao Huang, Chi-Fai Chan, Hongguang Li, Sam Lear, Jingyi Zong, Wing-Yan Wong, Magnolia Muk-Lan Lee, Brandon Dow Chan, Wai-Lun Chan, Wai-Sum Lo, Nai-Ki Mak, Maria Li Lung, Hong Lok Lung, Sai Wah Tsao, Graham S. Taylor, Zhao-Xiang Bian, William C. S. Tai, Ga-Lai Law, Wing-Tak Wong, Steven L. Cobb, Ka-Leung Wong
Journal: Nature Biomedical Engineering (2017)
Darbepoetin alfa (DA) 200 mcg every 2 weeks (Q2W) vs epoetin alfa (Epo) 40,000 U weekly (QW) in anemic patients (pts) receiving chemotherapy (ctx)
Authors: L. Schwartzberg, L. Yee, F. Senecal, V. Charu, D. Tomita, G. Rossi
Journal: Journal of Clinical Oncology (2004)

8063 Background: Both ASH/ASCO and NCCN evidence-based guidelines for the treatment of ctx-induced anemia (CIA) recommend achievement and maintenance of hemoglobin (Hb) near 12 g/dL to assure optimal quality of life and transfusion independence. Therefore, determining the ability to achieve and maintain Hb near 12 g/dL may be a useful approach to evaluate clinical effectiveness of erythropoietic therapies. Methods: Data from a randomized head-to-head comparison of DA (Aranesp®) Q2W vs Epo QW in pts with breast, lung, or gynecologic cancer were analyzed. Eligibility criteria: ≥ 18 years old, receiving multicycle ctx, anemic (Hb ≤ 11.0 g/dL), ≥ 8 weeks (wks) of planned ctx, Karnofsky status ≥ 50%, and adequate renal and liver function. Pts were randomized 1:1 to receive either DA 200 mcg Q2W or Epo 40,000 U QW for up to 16 wks (dose increase after 4 wks if Hb rise < 1 g/dL). A target Hb range of 11 to 13 g/dL was selected based on the study design, which required dose withholding if Hb > 13 g/dL. Results: This analysis included data through wk 17 (after 16 wks) for the first 210 pts (DA [n=105] and Epo [n=105]) with at least 1 dose of study drug. Baseline (BL) characteristics were similar, with mean (SD) BL Hb of 10.4 (0.8) g/dL for DA and 10.5 (0.8) g/dL for Epo. Mean (95% CL) change in Hb from BL (excluding effects of transfusion) through wk 17 was 1.4 (1.1, 1.7) g/dL for DA and 1.5 (1.2, 1.8) g/dL for Epo. The Kaplan-Meier (95% CL) estimate of proportion of pts who had a transfusion from wks 1–17 was 21% (12, 29) for DA and 19% (12, 27) for Epo. Data on achievement and maintenance of the target Hb range are provided below (table). Conclusions: These results suggest that DA 200 mcg Q2W and Epo 40,000 U QW have comparable efficacy in achieving and maintaining Hb of 11 to 13 g/dL and in reducing transfusions in both pts with BL Hb < 10 and ≥ 10 g/dL. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Inc. Amgen, Inc. Amgen, Inc. Amgen, Inc. Amgen, Inc.
Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.
Authors: Giuseppe Giaccone, Ariel Lopez-Chavez, Anish Thomas, Arun Rajan, Mark Raffeld, Regan M. Duffy, Betsy Morrow, Yisong Wang, Corey Allan Carter, Udayan Guha, Keith Killian, Christopher Y. Lau, Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer, Christopher L. Corless, Carol Beadling, Andrea Warrick, Eva Szabo
Journal: Journal of Clinical Oncology (2013)

7513 Background: CUSTOM is the first completed prospective clinical trial using molecular selection for treatment assignments into multiple targeted therapy arms and in multiple cancer histological subtypes concurrently. Methods: All patients with advanced NSCLC, SCLC or TM were eligible to participate in the study. Oncogenic mutations, amplifications or translocations in 12 genes detected in CLIA-certified laboratories were used to assign patients to 1 of 5 biomarker/treatment groups per histological subtype: EGFR mutations/erlotinib; KRAS, NRAS, HRAS or BRAF mutations/AZD6244; PIK3CA, AKT or PTEN mutations/MK2206; ERBB2 mutations or amplifications/lapatinib; and KIT or PDGFRA mutations/sunitinib; or to standard-of-care therapy. For each arm, the study was conducted as an optimal two-stage phase II trial in favor of a response rate of 40% or more. Results: 668 patients were enrolled at two academic institutions. The most frequent genetic alterations in NSCLC were KRAS and EGFR mutations (25.2 and 19.7% respectively), ALK rearrangements 7.8%, HER2 amplifications 2.7% and mutations in PIK3CA 2.5%, BRAF 1.9%, HRAS 1.5%, ERBB2 1.7%, AKT1 0.4%, and NRAS 0.7%. PTEN mutation analysis was only feasible in 13 patients with NSCLC of which 3 were positive (23%). The most frequent genetic alterations in SCLC were mutations in PIK3CA 6.5%, ERBB2 amplifications 5.3% and mutations in HRAS 3.4%, AKT1 2.2%, BRAF 2% and KRAS 2%. The most frequent genetic alterations in TMs were HER2 amplifications 7.7% and mutations in HRAS 4.7%, PIK3CA 1.4% and EGFR 1.4%. Only 6.2% (n=42) of patients met criteria for enrollment into the treatment arms of the study. Efficacy analyses including response rates will be presented. Conclusions: CUSTOM is the first completed prospective clinical trial demonstrating the feasibility of conducting efficacy analyses of multiple biomarker-matched therapies in multiple cancer histological subtypes concurrently. CUSTOM is also the largest prospective molecular profiling study of patients with SCLC and TMs. Clinical trial information: NCT01306045.
DOES INTRA-AORTIC BALLOON PUMP PLACEMENT DURING HOSPITALIZATION COURSE FOR TRANSCATHETER AORTIC VALVE REPLACEMENT PORTENT A WORSE CLINICAL OUTCOME?
Authors: Konstantinos V. Voudris, Richard B. Devereux, Dmitriy Feldman, Robert Minutello, Luke Kim, Harsimran Singh, Geoffrey Bergman, Arash Salemi, Shing-Chiu Wong
Journal: Journal of the American College of Cardiology (2017)
Risque de cancer et d'invasion sous-muqueuse des tumeurs à extension latérale (LST) colo-rectales et capacité de détection du cancer par les endoscopistes
Authors: H Soliman, B Brieau, MA Guillaumot, S Leblanc, M Barret, M Camus, J Dréanic, C Prieux-Klotz, M Dior, B Terris, R Coriat, F Prat, S Chaussade
Journal: Endoscopy (2017)

Les LSTs (laterally spreading tumors) sont définies comme des lésions > 10 mm de diamètre, avec une hauteur verticale minime et une extension latérale. Elles sont classées en 2 catégories chacune séparés en 2 sous types: granulaire (LST-G) avec ou sans macronodule, ou non granulaire (LST-NG) plane (IIa) ou déprimée (IIc). Chaque sous type est associé à un risque de cancer superficiel (T1) avec ou sans envahissement de la sous muqueuse (T1sm) dont la profondeur d'invasion permet de déterminer le traitement le plus adapté (mucosectomie, dissection sous muqueuse voire traitement chirurgical). L'objectif de notre étude était de rapporter les caractéristiques des LST traitées endoscopiquement dans une population occidentale, et d'évaluer la capacité de détection du cancer par l'endoscopiste avant la réalisation du geste.
Effect of CHRNA9 polymorphisms and passive smoking on the risk of breast cancer in Taiwan.
Authors: Yi-Chen Hsieh, Chia-Hwa Lee, Shih-Hsin Tu, Chih-Hsiung Wu, Mao-Chih Hsieh, Chin-Sheng Hung, Ching-Wen Chuang, Hung-Yi Chiou
Journal: Journal of Clinical Oncology (2014)

1593 Background: Previous studies have indicated that smoking exposure is associated with increased breast cancer risk, and α9-nicotine acetylcholine receptors (α9-nAChRs) were involved in breast tumorigenesis. However, there are no studies exploring the α9-nAChRs genes (CHRNA9) and cigarette smoking exposure together on breast cancer risk. Methods: A case-control study was conducted on 737 breast cancer patients and 719 age-matched healthy controls. Three single nucleotide polymorphisms (SNPs) of CHRNA9 located on promoter were genotyped and compared between cases and controls to identify these SNPs associated with breast cancer susceptibility. A dual-luciferase reporter assay was used to analyze the promoter activity of these SNPs of CHRNA9 gene. Results: CHRNA9 -885A/T and -823A/G polymorphisms showed a significant association with susceptibility of breast cancer. Passive cigarette smoking and risk genotypes of -823A/G of CHRNA9 gene had synergistic effects on the risk of breast cancer. The odds ratio for the interaction and the attributable proportion from the interaction and synergy index were 6.3, 0.56 and 2.6, respectively. These findings indicated a multiplicative interaction between passive cigarette smoking and CHRN9 gene. The results further confirmed that the risk genotype of -823A/G of CHRNA9 exhibited stronger transcriptional activation activity than the wild type (P<0.05). Conclusions: Our findings support that a significant interaction effect exists between CHRNA9 gene and passive cigarette smoking on breast cancer patients.
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.
Authors: Ami P. Jhaveri, Maysa M. Abu-Khalaf, Michael DiGiovanna, Lajos Pusztai, Erin Wysong Hofstatter, Tara Beth Sanft, Noelle Marie Sowers, Bonnie Lurie, Andrea Silber, Debra S. Brandt, Howard S. Hochster, Jill Lacy, Stacey Stein, Gina G. Chung
Journal: Journal of Clinical Oncology (2014)

2561 Background: Combination of sorafenib (S) and capecitabine (C) has shown clinical activity in single arm and randomized phase II trials of patients (pts) with metastatic breast (B) or GI (G) tumors. We sought an alternative schedule for C and S to reduce toxicity based on studies using the bi-weekly schedule for C and flat-dose administration. Study objectives are to assess safety, dose limiting toxicity (DLT), and maximum tolerated dose (MTD) of bi-weekly C and daily S. Secondary aims are efficacy, overall response rate, and duration of response. Methods: 19 pts with metastatic B or G tumors were enrolled to assess MTD and safety of C 1000mg bid flat dosing on days 1-7 and 15-21 of a 28 day cycle and S, 200mg AM/400mg PM given on a continuous basis. DLT definitions were predefined. Responses were defined using RECIST 1.0. Results: 19 pts with median age 55 (range 34-79) were treated. 14 pts had metastatic breast cancer; 5 pts had GI cancers. Median # of prior lines of chemotherapy in the metastatic setting was 1 (range 0-7). 2 pts are still on study. Median # cycles on study were 2 (range 1-5). Cycle 1 DLT were grade 3 pain in extremity (2 pts); grade 4 increased lipase (1 pt). Other grade 3/4 toxicities are summarized in Table. 16 pts are evaluable for response (12B, 4G). 2 pts with B tumors had partial response, 5 pts (3B, 2G) had stable disease, and 9 pts (7B, 2G) had disease progression. Conclusions: MTD was C 2,000mg 7 days on/7 days off and S 600mg daily. Despite overlapping toxicities of C and S combination, this dosing schedule is well tolerated and has sufficient clinical activity in pts with heavily pretreated metastatic breast and GI cancers to suggest further testing. Clinical trial information: NCT01640665. Treatment-related adverse events. Adverse events Grade 3 #pts Grade 4 #pts Fatigue 5 0 Hand-foot syndrome 5 0 Hypophosphatemia 4 0 Diarrhea 2 0 Pain in extremity 2 0 Nausea 2 0 Vomiting 1 0 Increased alkaline phosphatase 1 0 Hypertension 1 0 Increased lipase 0 1 Hyponatremia 1 0 Increased amylase 1 0 Anorexia 1 0 Rash (maculopapular) 1 0 Anemia 1 0
Human Cardiac Progenitors Isolated From Young Donors Harbor a Less Mature Phenotype Compared to Progenitors From Adult Donors
Authors: Ann-Sophie Walravens, Lara Ottavani, Maarten Vanhaverbeke, Hilde Gillijns, Nina Vanden Driessche, Sander Trenson, Aernout Luttun, Jens-Uwe Voigt, Bart Meyns, Paul Herijgers, Filip Rega, Bart Meuris, Ruth Heying, Maurilio Sampaolesi, Stefan Janssens
Journal: Circulation (2016)
Exploring educational gaps in myelodysplastic syndromes in medical students and internal medicine residents: A dual-institution survey.
Authors: Catherine Callaghan Coombs, Kristin Wiese, Carlos deCastro, Jamile M. Shammo
Journal: Journal of Clinical Oncology (2013)

7118 Background: Myelodysplastic syndromes (MDS) are a heterogeneous and poorly understood group of disorders. Prior studies have focused on patient and provider understanding of these disorders; however, no study to our knowledge has been conducted to explore educational gaps of medical students and medicine residents. The hypothesis of this work is that MDS are poorly understood by trainees, but this could be improved after education. Methods: A nine question survey pertaining to definition, diagnosis, risk assessment and survival in MDS was sent to medical students and medicine residents a week prior to a lecture on MDS. At Duke, the lecture was a senior resident talk; at Rush, it was a medicine grand rounds by a hematology attending. The survey was resent to the initial groups 15 days after the lectures, but only those who attended the lecture were invited to take it. Results: At Duke, the response rate was 141 out of 255 (55%); at Rush, it was 65 out of 414 (16%). Responses for the questions were similar at both institutions with no statistical difference in the percent of correct responses by institution. 83.7% said that anemia was not a normal consequence of aging. 82.4% acknowledged that a bone marrow biopsy is required to diagnose MDS. 57.6% said anemia was the most common hematologic manifestation of MDS. 40.4% said that a hemoglobin of &lt;10 should be referred to hematology. 36.1% said the bone marrow in MDS is hypercellular. 17.6% said MDS transforms to AML in 30% of cases. 11.2% identified MDS as a cause of macrocytic anemia. Only 11.1% identified MDS as a malignancy, and 5.5% identified the average survival of high-risk IPSS stage MDS as 0.4 years. In post-lecture surveys (n= 23), knowledge largely improved. However, given low number of responses, this reached statistical significance in only four of nine questions. Conclusions: MDS are poorly understood by both medical students and residents, especially in regard to the definition as a malignancy, prognosis, and risk of AML evolution. We propose that educational efforts aimed at early trainees would improve these knowledge deficits, in addition to the medical care of patients with MDS. The study is limited by the post-survey completion rate.
Different Cytogenetic Patterns in Specified Categories of Secondary AML: Results of a Population-Based Registry Study,
Authors: Jan M. Norgaard, Lene S.G. Oestgaard, Mette K. Andersen, Maria Kallenbach, Preben Johansen, Knud Bendix, Gitte Kerndrup, Birgitte Preiss, Inge Dufva, Susanne Timshel, Joergen Kristensen, Peter de Nully Brown
Journal: Blood (2011)
EFFECTS OF LOW MOLECULAR WEIGHT HEPARIN VERSUS DABIGATRAN ON PLATELET AGGREGATION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Authors: Flavia Bittar Britto Arantes, Fernando Menezes, Andre Franci, Carlos Barbosa, Talia F. Dalçoquio, Carlos K. Nakashima, Aline Ferrari, Marco Scanavini Filho, Remo Furtado, Luciano Baracioli, Jose Ramires, Roberto Kalil-Filho, Jose Nicolau
Journal: Journal of the American College of Cardiology (2017)
Remitting Seronegative Symmetrical Synovitis With Pitting Edema
Authors: Jianjie Wang, Chaoyu Pu, Zhenchang Wang, Jigang Yang
Journal: Clinical Nuclear Medicine (2017)

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare condition in the elderly and can appear as a first presentation of various types of rheumatic and malignant diseases. We presented a 62-year-old man with the diagnosis of RS3PE based on the clinical sign and laboratory data. Because of the possibility of associated malignancies in RS3PE, FDG PET/CT was performed to exclude occult tumors. The images showed multiple, symmetrically, diffusely increased F-FDG uptake in the soft tissue around joints and bones in the shoulders, hips, knees, and ankles.
The relationship between nasopharyngeal <scp>CCL</scp>5 and microbiota on disease severity among infants with bronchiolitis
Authors: K. Hasegawa, J. M. Mansbach, N. J. Ajami, J. F Petrosino, R. J. Freishtat, S. J. Teach, P. A. Piedra, C. A. Camargo 
Journal: Allergy (2017)

Abstract Emerging evidence suggests that the airway microbiota plays an important role in viral bronchiolitis pathobiology. However, little is known about the combined role of airway microbiota and CCL 5 in infants with bronchiolitis. In this multicenter prospective cohort study of 1005 infants (age &lt;1 year) hospitalized for bronchiolitis during 2011‐2014, we observed statistically significant interactions between nasopharyngeal airway CCL 5 levels and microbiota profiles with regard to the risk of both intensive care use ( P interaction =.02) and hospital length‐of‐stay ≥3 days ( P interaction =.03). Among infants with lower CCL 5 levels, the Haemophilus ‐dominant microbiota profile was associated with a higher risk of intensive care use ( OR , 3.20; 95% CI , 1.18‐8.68; P =.02) and hospital length‐of‐stay ≥3 days ( OR , 4.14; 95% CI , 2.08‐8.24; P &lt;.001) compared to the Moraxella ‐dominant profile. Conversely, among those with higher CCL 5 levels, there were no significant associations between the microbiota profiles and these severity outcomes (all P ≥.10).
Carotid stenosis in patients with atrial fibrillation
Authors: Merrill C. Kanter, Charles H. Tegeler, Lesly A. Pearce, Jesse Weinberger, William M. Feinberg, David C Anderson, Camilo R. Gomez, John F. Rothrock, Cathy M. Helgason, Robert G. Hart
Journal: JAMA Internal Medicine (1994)
SEVERE DISSECTION PROPAGATION DURING DIAGNOSTIC ANGIOGRAPHY OF A YOUNG FEMALE PRESENTING WITH SELF LIMITING CHEST PAIN: A CASE OF SPONTANEOUS CORONARY ARTERY DISSECTION
Authors: Sandrine Lebrun, Tarak Rambhatla, Craig Basman, Satjit Bhusri, Michael Kim
Journal: Journal of the American College of Cardiology (2017)
COST-EFFECTIVENESS OF CORONARY ARTERY CALCIUM TESTING AMONG STATIN CANDIDATES ACCORDING TO THE AMERICAN COLLEGE OF CARDIOLOGY AND AMERICAN HEART ASSOCIATION CHOLESTEROL GUIDELINES
Authors: Jonathan Hong, Ron Blankstein, Michael Blaha, Roger Blumenthal, Alejandro Arrieta, William Padula, Harlan Krumholz, Khurram Nasir
Journal: Journal of the American College of Cardiology (2017)
Impact of age on treatment and survival in patients with small cell lung cancer.
Authors: Harminder Singh Takhar, Shawgi Sukumaran, Marleesa Ly, Christos Stelios Karapetis, Amitesh Chandra Roy, Ganessan Kichenadasse, Bogda Koczwara
Journal: Journal of Clinical Oncology (2013)

e20577 Background: Elderly patients are underrepresented in clinical trials, yet account for significant group with small cell lung cancer (SCLC). We examined if the age of the patients, &lt;70yrs vs &gt;70yrs, impacted outcome. Methods: SCLC pts were identified by searching the hospital cancer registry from 1999 to 2009. Pt characteristics, management and outcomes were collated by reviewing clinical records. Survival analysis was performed. Results: From 168 SCLC pts, 49 (27 males, 22 females) had limited stage (LS) and 113 (71 males, 42 females) extensive stage (ES) SCLC. LS cohort, 27 pts were &lt;70yrs and 22 were &gt;70yrs. The overall group survival was not statistically different, with median overall survival of 12.4 months for &lt;70yrs and 7.8 months for &gt;70yrs (p=0.064). However, 44 pts who had active treatment, including chemoradiotherapy, chemotherapy alone, radiotherapy alone, there was statistically improved survival between &lt;70yrs vs &gt;70yrs of 12.8 months vs 8.2 months (p=0.05). There was no significant difference in proportion of pts who received active treatment between the two groups (96.2% vs 95.4% p =0.882). The number of pts completing treatment was not statistically different between the two age groups (70.8% vs 54.5% p = 0.53) In the ES cohort, 45 pts were &lt;70yrs and 68 were &gt;70yrs. The overall group survival was significantly worse in the &gt;70yrs with MOS 3.8 months for &gt;70yrs and MOS 6.9 for &lt;70yrs (p=0.0087). In pts who had active treatment, significantly higher proportion of pts &lt;70yrs received active treatment, including chemoradiotherapy, chemotherapy alone and radiotherapy alone, (77% versus 69%, p= 0.015). In pts who had active treatment, the survival was not statistically different, MOS &lt;70yrs 7.4 months vs &gt;70yrs 5.9 months (p= 0.088). Significantly less pts &gt;70yrs vs &lt;70yrs completed treatment (20% versus 39% p = 0.032). Conclusions: In LS SCLC, comparing treated patients &lt;70yrs vs &gt;70yrs, patients &gt;70yrs had reduced survival, this may be related to patient factors or tumour biology. In ES SCLC, comparing patients&lt;70yrs vs &gt;70yrs, patients &gt;70yrs had worse survival overall, less likely to receive active treatment and less likely to complete treatment, again this may reflect a difference in patient factors or tumour biology.
Dermoscopic Clues for Diagnosing Melanomas That Resemble Seborrheic Keratosis
Authors: Cristina Carrera, Sonia Segura, Paula Aguilera, Massimiliano Scalvenzi, Caterina Longo, Alicia Barreiro, Paolo Broganelli, Stefano Cavicchini, Alex Llambrich, Pedro Zaballos, Luc Thomas, Josep Malvehy, Susana Puig, Iris Zalaudek
Journal: JAMA Dermatology (2017)

Melanomas that clinically mimic seborrheic keratosis (SK) can delay diagnosis and adequate treatment. However, little is known about the value of dermoscopy in recognizing these difficult-to-diagnose melanomas.To describe the dermoscopic features of SK-like melanomas to understand their clinical morphology.This observational retrospective study used 134 clinical and dermoscopic images of histopathologically proven melanomas in 134 patients treated in 9 skin cancer centers in Spain, France, Italy, and Austria. Without knowledge that the definite diagnosis for all the lesions was melanoma, 2 dermoscopy-trained observers evaluated the clinical descriptions and 48 dermoscopic features (including all melanocytic and nonmelanocytic criteria) of all 134 images and classified each dermoscopically as SK or not SK. The total dermoscopy score and the 7-point checklist score were assessed. Images of the lesions and patient data were collected from July 15, 2013, through July 31, 2014.Frequencies of specific morphologic patterns of (clinically and dermoscopically) SK-like melanomas, patient demographics, and interobserver agreement of criteria were evaluated.Of the 134 cases collected from 72 men and 61 women, all of whom were white and who had a mean (SD) age of 55.6 (17.5) years, 110 (82.1%) revealed dermoscopic features suggestive of melanoma, including pigment network (74 [55.2%]), blue-white veil (72 [53.7%]), globules and dots (68 [50.7%]), pseudopods or streaks (47 [35.1%]), and blue-black sign (43 [32.3%]). The remaining 24 cases (17.9%) were considered likely SKs, even by dermoscopy. Overall, lesions showed a scaly and hyperkeratotic surface (45 [33.6%]), yellowish keratin (42 [31.3%]), comedo-like openings (41 [30.5%]), and milia-like cysts (30 [22.4%]). The entire sample achieved a mean (SD) total dermoscopy score of 4.7 (1.6) and a 7-point checklist score of 4.4 (2.3), while dermoscopically SK-like melanomas achieved a total dermoscopy score of only 4.2 (1.3) and a 7-point checklist score of 2.0 (1.9), both in the range of benignity. The most helpful criteria in correctly diagnosing SK-like melanomas were the presence of blue-white veil, pseudopods or streaks, and pigment network. Multivariate analysis found only the blue-black sign to be significantly associated with a correct diagnosis, while hyperkeratosis and fissures and ridges were independent risk markers of dermoscopically SK-like melanomas.Seborrheic keratosis-like melanomas can be dermoscopically challenging, but the presence of the blue-black sign, pigment network, pseudopods or streaks, and/or blue-white veil, despite the presence of other SK features, allows the correct diagnosis of most of the difficult melanoma cases.